Consumer Medicine Information
NOTICE: This Consumer Medicine Information (CMI) is intended for persons
living in Australia. This page contains answers to some common
. It does
not contain all the information that is known about
. It does not take the
place of talking to your doctor or pharmacist. All medicines have risks
and benefits. Your doctor has weighed the risk of you using this medicine
against the benefits he/she expects it will have for you. If you have
any concerns about using this medicine, ask your doctor or pharmacist.
Bookmark or print this page, you may need to read it again.
What REMICADE is used for
REMICADE contains the active ingredient, infliximab. Infliximab is a monoclonal antibody that is produced from human and mouse
proteins by recombinant technology. Monoclonal antibodies are proteins that recognise and bind to certain special proteins
in the body.
Infliximab acts by binding to a special protein in the body called tumour necrosis factor alpha (TNFα). In people with diseases
such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis,
the body produces too much TNFα, which can cause the body's immune system to attack normal healthy parts of the body. REMICADE
can block the damage caused by too much TNFα.
Rheumatoid arthritis is an inflammatory disease of the joints. REMICADE is used to reduce the signs and symptoms of rheumatoid
arthritis and to prevent damage to the joints. You will also be given a disease-modifying medicine called methotrexate.
Ankylosing spondylitis is an inflammatory disease of the spine. REMICADE can reduce the signs and symptoms of ankylosing spondylitis,
thereby improving physical function.
Psoriatic arthritis is an inflammatory disease of the joints in which psoriasis usually occurs in association with arthritis.
Often the fingers and toes are affected, although it may occur in other parts of the body. REMICADE is used to reduce the
signs and symptoms of psoriatic arthritis and improve the physical function in adults who have not responded well enough to
previous treatments with other disease-modifying anti-rheumatic drugs (DMARDS). REMICADE may be given alone or in combination
Psoriasis is an inflammatory disease of the skin. REMICADE is used to treat patients with moderate to severe psoriasis who
have not responded well enough to treatments such as phototherapy or conventional systemic treatments, or when these treatments
are not appropriate.
Crohn's disease is a chronic inflammatory disease of the bowel. It may also affect any part of the gut. REMICADE is used to
treat moderate to severe Crohn's disease in adult patients and in children and adolescent patients (6 to 17 years old) who
have not responded well enough to other treatments.
REMICADE can also reduce the number of abnormal openings from the bowel through the skin (called draining enterocutaneous
fistula), a common complication of Crohn's disease.
Ulcerative colitis is an inflammatory disease of the bowel. REMICADE is used to treat the signs and symptoms of ulcerative
colitis in adult patients and in children and adolescent patients (6 to 17 years old) who have not responded well enough to
Do not give REMICADE to children with Crohn's disease or ulcerative colitis who are younger than 6 years.
Do not give REMICADE to children and adolescents with any other disease.
Your doctor, however, may prescribe REMICADE for another purpose.
Ask your doctor if you have any questions about why REMICADE has been prescribed for you.
Before you are given REMICADE
When you must not be given it
Do not use REMICADE if you have an allergy to mouse proteins or any of the ingredients listed at the end of this leaflet.
Some of the symptoms of an allergic reaction to REMICADE may include skin rash, hives, fatigue, wheezing, difficulty in breathing,
and/or low blood pressure.
Do not use REMICADE if you have severe infections such as tuberculosis and infected abscesses, a repeating infection or have
had repeating infections.
Do not use REMICADE if you are already taking another medicine for arthritis, which contains the substance called anakinra.
If you have never been given REMICADE and have congestive heart failure, you should not use it.
Before you are given it
Tell your doctor if you:
currently have an infection, or if you are prone to infections, or if you have a history of infections
REMICADE may affect the normal immune response. You might get infections more easily. Some cases of serious infections, including
tuberculosis (TB) and sepsis have been reported in patients treated with REMICADE.
have ever had or been in close contact with TB, even if you were treated for it.
have ever had or had been in close contact with hepatitis B
Reactivation of hepatitis B have been reported in people treated with TNFα blockers. However, these reports are very rare.
have lived in or travelled to an area where fungal infections called histoplasmosis, coccidioidomycosis, or blastomycosis
are common. Ask your doctor if you don't know if these infections are common in the area in which you have lived in or travelled
These infections are caused by fungus that can affect the lungs or other parts of your body.
have had cancer
A type of blood cancer called lymphoma has been reported in patients receiving TNF blockers. The reports are rare but are
more frequent than expected for people in general. Cancers, other than lymphoma, have also been reported.
have a long history of Crohn's disease rheumatoid arthritis, ankylosing spondilitis or psoriatic arthritis, especially if
you have a highly active disease and/or have been taking medicine that reduces the activity of the body's natural defences.
You may be more likely to develop infections and lymphomas than people in general, even without receiving TNF blockers such
are pregnant or plan to become pregnant
Like most medicines, REMICADE is not recommended in pregnancy.
You must use adequate contraception to avoid falling pregnant.
Like most medicines, REMICADE is not recommended while breast-feeding. It is not known whether REMICADE passes into breastmilk.
have or have had a disease that affects the nervous system such as multiple sclerosis and seizures, or if you experience any
numbness, weakness, tingling, or sight disturbances.
suffer from congestive heart failure.
Steps must be taken to monitor any changes to your condition during treatment with REMICADE.
have ongoing blood disorders or a history of blood disorders.
are scheduled to receive any vaccines
Patients receiving REMICADE should not receive some types of vaccines.
Your doctor will discuss with you the benefits of using REMICADE against the potential risks.
Taking or being given other medicines
Tell your doctor if you are taking any other medicines, including any that you buy without a prescription from your pharmacy,
supermarket or health food shop.
Some medicines may affect the way other medicines work.
Do not use REMICADE is you are already taking another medicine for arthritis, which contains the substance called anakinra.
Tell your doctor if you are already taking another medicine for arthritis, which contains the substance called abatacept.
Tell your doctor if you are receiving other treatments
for rheumatoid arthritis
for ankylosing spondylitis
for psoriatic arthritis
for psoriasis, such as phototherapy or other treatments
for Crohn's disease
for ulcerative colitis
to prevent rejection in organ transplantation.
Tell your doctor you are taking REMICADE before receiving any vaccinations. Some vaccinations should not be given while you
are on REMICADE.
Your doctor or pharmacist will be able to tell you what to do when being given REMICADE with other medicines.
How REMICADE is given
REMICADE is only available on prescription. REMICADE is given in a drip into a vein (called an infusion) over at least 2
If you were able to tolerate the first 3 two-hour infusions, your doctor may decide to give your next REMICADE infusion over
a period of not less than 1 hour.
For children and adolescents (6-17 years) the infusion is given over at least 2 hours.
A period of observation follows treatment.
The recommended starting dose is an infusion of 3 mg/kg. You will get additional doses of 3 mg/kg at 2 and 6 weeks after
your first infusion and then every 8 weeks after that.
If, after 12 weeks of treatment, your arthritis does not respond well enough to the 3 mg/kg dose, your doctor may decide to
gradually increase your dose to a maximum of 7.5 mg/kg every 8 weeks.
You will also be taking methotrexate as part of your treatment.
The recommended starting dose is an infusion of 5 mg/kg. You will get additional doses of 5 mg/kg at 2 and 6 weeks after
your first infusion and then every 6 weeks after that.
The recommended starting dose is an infusion of 5 mg/kg. You will receive additional doses of 5 mg/kg at 2 and 6 weeks after
your first infusion, then every 8 weeks after that. REMICADE may be given alone or in combination with methotrexate.
The recommended starting dose is an infusion of 5 mg/kg. You will get additional doses of 5 mg/kg at 2 and 6 weeks after your
first infusion, and then every 8 weeks after that.
The recommended starting dose for Crohn's disease in adults and in children and adolescents (6 to 17 years); and for closure
of fistula in adult patients is an initial infusion of 5 mg/kg followed by additional doses of 5 mg/kg at 2 and 6 weeks after
your first infusion, and then every 8 weeks after that. In some cases, your doctor may decide to increase your dose up to
The recommended starting dose for ulcerative colitis in adults and in children and adolescents (6 to 17 years) is an infusion
of 5 mg/kg. You will get additional doses of 5 mg/kg at 2 and 6 weeks after your first infusion, and then every 8 weeks after
While you are being given REMICADE
Things you must do
Tell your doctor, nurse or pharmacist if the medicine starts to upset you or your symptoms become worse.
Tell your doctor or dentist that you are being treated with REMICADE before you undergo any surgical procedures.
Tell your doctor:
if symptoms of TB (persistent cough, weight loss, listlessness, fever), or any other infection appear. Do this immediately.
if symptoms of hepatitis B (upset stomach, loss of appetite, vomiting, tiredness, dark yellow or brown urine, and yellow eyes
or skin) appear. You must do this immediately.
that you are taking REMICADE before receiving any vaccinations.
Some vaccinations should not be given while you are being treated with REMICADE.
You should continue to take adequate contraceptive measures to avoid pregnancy.
Your doctor will also advise you not to breastfeed.
Things to be careful of
Tell your doctor if you think you have an infection.
REMICADE may affect the normal immune response. There is a possibility that you may be more prone to infections. You will
be watched closely for signs of infection.
Tell your doctor immediately if you develop a skin rash or hives.
Your doctor may discontinue REMICADE until the symptoms go away and then begin giving the medicine again. Symptoms will resolve
with appropriate treatment.
If you suffer from congestive heart failure, tell your doctor immediately if your condition worsens.
REMICADE is unlikely to make you drowsy. If you are tired, do not drive a car or work with machinery.
Tell your doctor, nurse, or pharmacist as soon as possible if you do not feel well while you are being given REMICADE.
All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment
if you get some of the side effects.
Generally, patients with rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, or psoriasis
already take several medicines to treat their disease. These medicines may themselves cause side effects.
If you get additional side effects or any new symptoms, please tell your doctor.
Ask your doctor or pharmacist to answer any questions you may have.
Do not be alarmed by the following list of possible side effects. You may not experience any of them.
During the infusion of REMICADE the following reactions may occur:
fever or chills
itchiness or hives
low blood pressure
high blood pressure
shortness of breath.
These reactions are more likely to occur during the first and second infusion but may also appear up to six months after the
Tell your doctor immediately if you notice any of the following:
pain or tenderness in chest, muscles, joints or jaw
swelling of the hands, feet, ankles, face, lips, mouth or throat, which may cause difficulty in swallowing or breathing
abnormal chest sounds
symptoms that may indicate heart failure, e.g. shortness of breath, especially with exercise or lying down, or swelling of
Tell your doctor or nurse as soon as possible if you notice any of the following:
nausea or vomiting
dizziness and light-headedness
shortness of breath
weight loss, muscle wasting
problems with urination
changes in the way your heart beats, for example, if you notice it beating faster
dry skin or increased sweating
new onset of psoriasis, mainly on the soles of the feet and on palms
worsening of rheumatoid arthritis.
There have been very rare cases where people taking REMICADE have developed liver problems. Signs that you could be having
a problem include:
jaundice (skin and eyes turning yellow)
dark-brown coloured urine
right-sided abdominal pain
severe fatigue (tiredness).
You should contact your doctor immediately if you develop any of these symptoms.
Tell your doctor if you notice any other effects.
Most of the side effects are mild to moderate in severity. Other side effects not listed above may also occur in some patients.
Some side effects may appear up to six months after the last infusion.
In clinical studies, more cancers were seen in patients who received TNF-blockers , including REMICADE, than patients who
did not receive these treatments.
In children and adults being treated with TNF-blockers, the chances of getting lymphoma or other cancers may increase. It
should be noted, however, that patients with longstanding and active rheumatoid arthritis or Crohn's disease may already have
a higher risk for developing cancers even without TNF-blockers, making it difficult to estimate the risk of developing cancers
in these patients. Nevertheless, the role of TNF-blockers in the development of cancers cannot be excluded.
A rare type of cancer called Hepatosplenic T-cell Lymphoma (HSTCL) has been reported rarely in adolescents and young adults
with Crohn's disease or ulcerative colitis who have received REMICADE. All of these patients were also receiving drugs known
as azathioprine or 6-mercaptopurine. No cases of HSTCL have been reported in patients receiving REMICADE only. HSTCL often
results in death. The role of TNF blockers in the development of cancers in children and adolescents remain unclear.
Talk to your doctor if you are concerned about this.
Skin cancers (melanoma and Merkel cell carcinoma) have been reported rarely in patients treated with TNF-blockers, including
Tell your doctor if you notice any new skin lesions during or after therapy or if existing lesions change appearance.
Cervical cancer may occur more frequently in women treated with REMICADE. Periodic screening of women treated with REMICADE
Patients with a lung disease called Chronic Obstructive Pulmonary Disease and who have a history of heavy smoking may have
an increased risk for getting cancer while being treated with REMICADE.
After REMICADE has been stopped
Tell your doctor immediately if:
you notice any of the following side effects, even if they occur several weeks after stopping treatment with REMICADE.
skin rash or hives
symptoms of TB (persistent cough, weight loss, listlessness, fever), or any other infection appear.
symptoms of hepatitis B (upset stomach, loss of appetite, vomiting, tiredness, dark yellow or brown urine, and yellow eyes
or skin) appear.
These symptoms may appear several months after your last REMICADE treatment.
You should continue to take adequate contraceptive measures to avoid pregnancy for at least 6 months after the last infusion
Your doctor will advise you not to breastfeed for at least 6 months after your last infusion of REMICADE.
Tell your doctor if you notice any other effects.
REMICADE should be stored at 2°C to 8°C (Refrigerate.) Do not use beyond the expiry date.
REMICADE may be stored at temperatures up to a maximum of 30°C for a single period of up to 12 months; but not exceeding the
original expiration date. The new expiration date should be written on the carton. Upon removal from refrigerated storage,
REMICADE cannot be returned to refrigerated storage.
REMICADE vials are for single use only. Any unused portion should be discarded.
What it looks like
REMICADE comes as a white powder in a glass vial.
Infliximab (recombinant) 100 mg per vial
sodium phosphate monobasic monohydrate
sodium phosphate dibasic dihydrate
JANSSEN-CILAG Pty Ltd
1-5 Khartoum Road
Macquarie Park NSW 2113 Australia
Telephone: 1800 226 334
Australian Registration Number
AUST R 73827
Date of Preparation:
15 April 2016